Attached files
| file | filename |
|---|---|
| EX-99.2 - MARIZYME INC | ex99-2.htm |
| EX-99.1 - MARIZYME INC | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2021 (January 11, 2021)
MARIZYME, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 000-53223 | 82-5464863 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
| 555 Heritage Drive, Suite 205, Jupiter Florida | 33458 | |
| (Address of principal executive offices) | (Zip Code) |
(561) 935-9955
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common | MRZM | OTC Markets |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging Growth Company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 8.01 Other Events
During the week of January 11 - 14, 2021, Dr. Neil Campbell, CEO of Marizyme, Inc. (“Marizyme”), virtually presented at the 39th Annual J.P. Morgan Health Care Conference the presentation as reflected in Exhibits 99.1 and 99.2.
Item 9.01 Financial Statement and Exhibits
(d) Exhibits
The following exhibits are filed herewith:
| Exhibit No. | Description of Exhibit | |
| 99.1 | Presentation | |
| 99.2 | Script for Presentation |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, Marizyme, Inc. has duly caused this current report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: February 26, 2021 | MARIZYME, INC. | |
| By: | /s/ Neil J. Campbell | |
| Dr. Neil J. Campbell | ||
| Chief Executive Officer | ||